Novo Nordisk Earnings Must Show GLP-1 Market Still Set for Big Growth
Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
$100 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today
Buying $100 In NVO: If an investor had bought $100 of NVO stock 5 years ago, it would be worth $261.75 today based on a price ...
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside
Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Jim Cramer Expects Novo Nordisk A/S (NVO) To Forecast A Good 2025
Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...